Wockhardt share news, announcements and annual reports
NSE: WOCKPHARMABSE: 532300Pharmaceuticals & BiotechnologySmall Cap
Wockhardt Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹1,896.50down ₹4.60 (0.24%)BSE ₹1,892.15
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,901.10.
2 Nov: open ₹1,903.10, high ₹1,915.00, low ₹1,864.10
52-week range of traded prices to 2 Nov 2026
₹1,086.70Low, 23 Mar 2026₹2,422.30High, 1 Jun 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹30,817 Cr311th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 75.35
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.24
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 6,06,59351.5% delivered
Wockhardt board meetings
142 filed, newest first. Page 3 of 3.
Jul 2014
31 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results (consolidated and standalone) of the Company for the quarter ended June 30, 2014. Further, pursuant to Company's code for prevention of insider trading, the Trading window is closed from July 31, 2014 to August 13, 2014 (both days inclusive). The Trading Window shall re-open 24 hours after the financial results are submitted to the stock exchanges.
May 2014
26 May · Board meeting
Board of Directors at its meeting held on May 26, 2014 has noted resignation of Mr. Vijay Khetan, Company Secretary & Compliance Officer with effect from May 30, 2014.14 May · Board meeting
Inter alia, to consider and approve the following items:(1). Approval of the Annual Audited Consolidated and Standalone Accounts of the Company for the year ended March 31, 2014. (2). Approval of the Audited Consolidated and Standalone financial results of the Company for the quarter and year ended March 31, 2014.(3). Recommendation of dividend on preference shares.Further, pursuant to Company's code for prevention of insider trading, the Trading window is closed from May 14, 2014 to May 27, 2014 (both days inclusive). The Trading Window shall re-open 24 hours after the financial results and intimation of dividend are submitted to the stock exchanges
Feb 2014
10 Feb · Board meeting
Board of Directors of the Company at its meeting held on February 09, 2014 has approved re-appointment of Dr. Huzaifa Khorakiwala, Executive Director and Dr. Murtaza Khorakiwala, Managing Director for a period of Five years w.e.f March 31, 2014 subject to the approval of members of the Company.
Jan 2014
28 Jan · Board meeting
Inter alia, for the following:(1) To consider and approve the unaudited financial results of the Company for the quarter and nine month ended December 31, 2013 .(2) Consideration of Interim Dividend.
Oct 2013
11 Oct · Board meeting
Inter alia, for the following:(1) To consider and approve the unaudited financial results of the Company for the quarter and half year ended September 30, 2013 .(2) Consideration of Interim Dividend.
Aug 2013
2 Aug · Board meeting
Inter alia to consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2013.
May 2013
27 May · Board meeting
Board of Directors of the Company at its meeting held on May 27, 2013 has considered appointment of Mr. V. Suresh as "President - Finance" of the Company.13 May · Board meeting
Inter alia, to consider and approve the following: (1) Approval of the Audited Consolidated and Standalone financial results of the Company for the quarter and year ended March 31, 2013. (2) Recommendation of dividend on preference shares and equity shares. Further the Company has informed that, in the Audit Committee meeting scheduled to be held on, May 27, 2013, the appointment of Mr. V. Suresh as President - Finance will also be considered.
Feb 2013
1 Feb · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and nine months ended December 31, 2012.
Nov 2012
2 Nov · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and half year ended September 30, 2012.
Jul 2012
23 Jul · Board meeting
Inter alia , to consider and approve the unaudited financial results of the company for the quarter ended June 30, 2012.
May 2012
10 May · Board meeting
Inter alia, to consider and approve the audited financial results of the Company for the quarter and year ended March 31, 2012.
Feb 2012
2 Feb · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and nine months ended December 31, 2011.
Nov 2011
18 Nov · Board meeting
Compensation Committee of the Board at its meeting held on November 12, 2011, inter alia, has approved the Grant of 1,540,000 Stock Options convertible into 1,540,000 equity shares of Rs. 5/- each (60,000 options @ Rs. 397/- per option; 60,000 options @ Rs. 365/- per option; 1,420,000 options @ Rs. 5/- per option) under Wockhardt Stock Option Scheme - 2011, in accordance with the provisions of Securities and Exchange Board of India (Employees Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999, to the selected employees of the Company and its subsidiaries.3 Nov · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and half year ended September 30, 2011.
Aug 2011
9 Aug · Board meeting
Board of Directors of the Company at its meeting held on August 09, 2011, inter alia, considered and approved Employee Stock option Scheme - 2011 (Wockhardt ESOS - 2011) and issuance of 25,00,000 stock options to the permanent bonafide employees and directors of the Company and its Holding and Subsidiary Company under Wockhardt ESOS - 2011. Each option covers one equity share and thus aggregate number of 25,00,000 equity shares of face value of Rs. 5/- each are covered under Wockhardt ESOS - 2011. The said issuance of ESOP will be subject to the approval of the members of the Company.
Jul 2011
28 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2011.
May 2011
10 May · Board meeting
Inter alia, to transact the following business : (1) To consider and approve the audited Standalone and Consolidated Financial Accounts of the Company for the year ended March 31, 2011; (2) To consider and approve the audited Financial Results of the Company for the quarter and year ended March 31, 2011.
Jan 2011
19 Jan · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and nine months ended December 31, 2010.
Nov 2010
1 Nov · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and half year ended September 30, 2010.
Aug 2010
13 Aug · Board meeting
Jul 2010
30 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2010.
May 2010
5 May · Board meeting
Inter alia, to transact the following business : (i) To consider and approve the audited Financial Accounts of the Company for a period of fifteen months ended March 31, 2010 ("Financial Year"). (ii) To consider and approve the audited Financial Results of the Company for the quarter and a period of fifteen months ended March 31, 2010 ("Financial Year").
Jan 2010
14 Jan · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and twelve months ended December 31, 2009.
Oct 2009
16 Oct · Board meeting
Inter alia, to consider and approve the unaudited financial results for the quarter and nine months ended September 30, 2009.
Jul 2009
20 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and half year ended June 30, 2009.
Apr 2009
24 Apr · Board meeting
Board of Directors at their meeting held on April 24, 2009 transacted the following business : (1) Approval of the notice of postal ballot along with the postal ballot form and calendar of events for obtaining consent of the members of the Company for sale / transfer / disposal of Animal Healthcare Business of the Company to its subsidiary/ any other entity /parties as may be decided by the Board as a going concern or otherwise at such price and on such terms and conditions as may be decided by the board.15 Apr · Board meeting
Interalia to transact the following business:-(1) To consider and approve the audited Financial Accounts of the Company for the year ended December 31, 2008. (2) To consider and approve the audited Financial Results of the Company for the quarter and year ended December 31, 2008. (3) To consider and approve unaudited financial results of the Company for the quarter ended March 31, 2009.
Mar 2009
31 Mar · Board meeting
On account of a potential restructuring of certain businesses of the Company and its subsidiaries which the Company is currently evaluating, the statutory audit of the accounts of the Company could not be completed as scheduled. The company expect that the audit of the annual accounts of the Company for the financial year ended December 31, 2008 would be completed by April 25, 2009 and will be published forthwith upon such completion. Further, at the Board Meeting held on March 31, 2009 the following business was transacted amongst others:(1). Mr. H F Khorakiwala, who is presently Chairman & Managing Director will continue as Executive Chairman on the Board and resign from the post of Managing Director.(2). The Board appointed Dr. Murtaza H. Khorakiwala as Additional Director and subject to the approval of members in general meeting, as Managing Director of the Company w.e.f. March 31, 2009.(3). The Board appointed Mr. Huzaifa H. Khorakiwala as Additional Director and subject to the approval of members in general meeting as Whole- time Director designated as Executive Director of the Company w.e.f. March 31, 2009.(4). In view of the adverse market conditions, liquidity constraints and debt burden, the Board decided to make a reference to Corporate Debt Restructuring Cell (CDR Cell) through ICICI Bank Limited, for financial restructuring of the debts of the Company, through Corporate Debt Restructuring Mechanism. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Mar · Board meeting
Interalia to transact the following business:-(1) To consider and approve the Audited Financial Accounts of the Company for the year ended December 31, 2008. (2) To consider and approve the Audited Financial Results of the Company for the quarter and year ended December 31, 2008. (3) To consider dividend, if any, to be recommended on equity shares for the year ended December 31, 2008.
Oct 2008
8 Oct · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and nine months ended September 30, 2008.
Jul 2008
14 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter and half year ended June 30, 2008.
Apr 2008
15 Apr · Board meeting
To consider and approve the unaudited financial results of the Company for the quarter ended March 31, 2008.
Feb 2008
5 Feb · Board meeting
For transacting the following business amongst others: (1) Approval of the audited accounts of the Company for the year ended December 31, 2007. (2) Publishing of the audited results for the quarter and year ended December 31, 2007. (3) Recommendation of final dividend.
Jan 2008
18 Jan · Board meeting
Vide its letter dated January 18, 2008, that: "A meeting of Board of Directors of the Company held today the following business was transacted amongst others:1) Subject to the approval of shareholders, creditors and regulatory bodies the Board provided its in-principle approval to demerge the new drug discovery programme and the innovative new technologies R&D. 2) Subject to the approval of the shareholders and regulatory bodies the board approved raising of funds upto US$ 200 million through issuance of equity / equity linked securities to expand its domestic and international business. 3) Convene an extra-ordinary general meeting of the members of the Company on February 20, 2008 for obtaining the approval of shareholders to raise funds upto US$ 200 million". Further, the Company has submitted to the Exchange a copy of the press release dated January 18, 2008, titled "Wockhardt to restructure its R&D business". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Jan · Board meeting
To consider the following: (1) In Principle approval of the board to demerge New Chemical Entities (NCE) R&D and certain high value products R&D carried out by the Company, subject to the approval of shareholders and other regulatory authorities. (2) Raising of funds through further issue of equity/ equity linked securities, subject to the approval of shareholders.
Oct 2007
10 Oct · Board meeting
For: 1) Approving the unaudited results of the Company for the quarter and nine months ended September 30, 2007; and 2) For considering the Interim Dividend for the year 2007.
Jul 2007
13 Jul · Board meeting
For approving the unaudited results of the Company for the quarter and half year ended June 30, 2007.
Apr 2007
12 Apr · Board meeting
For approving the unaudited results of the Company for the quarter ended March 31, 2007.
Mar 2007
1 Mar · Board meeting
For transacting the following business: 1) To consider Revocation of recommended dividend for the year ended December 31, 2006. 2) To consider payment of Interim Dividend for the year ended December 31, 2006. 3) To consider the fixing of Record Date for the purpose of payment of Interim Dividend. 4) To Consider Approval of Audited Accounts for the year ended December 31, 2006, after necessary changes as to Revocation of recommended dividend and payment of Interim Dividend.
Feb 2007
7 Feb · Board meeting
For transacting the following business amongst others :- (i) Approval of the audited accounts of the Company for the year ended December 31, 2006. (ii) Publishing of the audited results for the quarter and year ended December 31, 2006. (iii) Recommendation of dividend.